콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

동의어(들):

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C6H17NO7P2
CAS Number:
Molecular Weight:
277.15
MDL number:
UNSPSC 코드:
51111800
PubChem Substance ID:
NACRES:
NA.77

제품명

Neridronate, ≥97% (NMR), solid

설명

may contain <1% (w/w) inorganic salts

Quality Level

분석

≥97% (NMR)

양식

solid

색상

white

solubility

H2O: >5 mg/mL

저장 온도

2-8°C

SMILES string

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

InChI key

PUUSSSIBPPTKTP-UHFFFAOYSA-N

생화학적/생리학적 작용

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".
Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta.

픽토그램

Exclamation mark

신호어

Warning

유해 및 위험 성명서

예방조치 성명서

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

dust mask type N95 (US), Eyeshields, Gloves


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Patrizia D'Eufemia et al.
Pediatric research, 63(2), 203-206 (2007-12-20)
Prostaglandin E2 (PGE2) is an activator of bone remodeling, and increase levels of PGE2 are found in several disorders characterized by chronic inflammation. Bisphosphonates are used in the treatment of osteogenesis imperfecta (OI), an inherited disorder characterized by bone fragility
Silvano Adami et al.
Calcified tissue international, 83(5), 301-307 (2008-10-24)
Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramuscularly (IM), was tested in a phase 2
M Benucci et al.
Clinical and experimental rheumatology, 27(4), 567-573 (2009-09-24)
To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and
Pietro Persiani et al.
Medicine, 96(20), e6766-e6766 (2017-05-18)
The purpose of this study is to compare the results of 2 techniques, tension band wiring (TBW) and fixation with screws, in olecranon fractures in children affected with osteogenesis imperfecta (OI) type I. Between 2010 and 2014, 21 olecranon fractures
Davide Gatti et al.
Bone, 50(3), 739-742 (2011-12-20)
The benefits coming from long-term treatment of postmenopausal osteoporosis with bisphophonates are limited by a coupled decrease in bone formation. The objective of this study is to determine whether this decrease in bone formation is associated with changes in serum

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.